| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA944: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer |
|
Medicine details |
|
| Medicine name | durvalumab (Imfinzi®) |
| Formulation | intravenous infusion |
| Reference number | 5018 |
| Indication | with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 15/11/2023 |
| NICE guidance | |